Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Axcan Acquires Photofrin Rights from QLT
May 2000
MONT SAINT-HILAIRE, Quebec, Canada, May 2 -- Axcan Pharma Inc. has signed an agreement to acquire worldwide rights to Photofrin -- a drug approved for use in photodynamic therapy for the treatment of certain cancers -- from QLT PhotoTherapeutics Inc. (QLT) of Vancouver.
Axcan's acquisition of the rights to the drug involves a stock subscription agreement under which QLT will purchase 1,283,333 shares of Axcan common stock for $19,250,000 (CDN), or $15 per share (CDN). The transaction between the two companies also involves an asset purchase agreement, which calls for QLT to sell, license or sub-license to Axcan all QLT's rights, title and interest in Photofrin for $39.25 million (CDN). This agreement includes the sale of QLT's European subsidiary, which owns the European registrations for Photofrin.

News & Features

Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,
x We deliver – right to your inbox. Subscribe FREE to our newsletters.